MA30966B1 - Combinaison d'inhibiteurs de iap et d'inhibiteurs de flt3 - Google Patents
Combinaison d'inhibiteurs de iap et d'inhibiteurs de flt3Info
- Publication number
- MA30966B1 MA30966B1 MA31946A MA31946A MA30966B1 MA 30966 B1 MA30966 B1 MA 30966B1 MA 31946 A MA31946 A MA 31946A MA 31946 A MA31946 A MA 31946A MA 30966 B1 MA30966 B1 MA 30966B1
- Authority
- MA
- Morocco
- Prior art keywords
- combination
- inhibitors
- iap
- flt3
- active agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'INVENTION CONCERNE DES COMBINAISONS D'INHIBITEURS DE IAP ET D'INHIBITEURS DE FLT3, DES COMPOSITIONS PHARMACOLOGIQUES COMPRENANT UNE TELLE COMBINAISON, DES PROCÉDÉS DE TRAITEMENT DE MALIGNITÉS HÉMATOLOGIQUES, NOTAMMENT LA LEUCÉMIE AIGUË MYÉLOÏDE (LAM). LES COMPOSITIONS PHARMACOLOGIQUES DE L'INVENTION COMPRENNENT UN COMPOSÉ INHIBANT LA LIAISON DE LA PROTÉINE SMAC (ACTIVATEUR DE CASPASE DÉRIVÉ DE MITOCHONDRIES DITES SECONDAIRES) À L'INHIBITEUR D'APOPTOSE (INHIBITEUR DE IAP) COMBINÉ À AU MOINS UN PRINCIPE PHARMACEUTIQUEMENT ACTIF. L'INVENTION CONCERNE ÉGALEMENT L'UTILISATION DE CES COMBINAISONS POUR TRAITER UNE LEUCÉMIE AIGUË MYÉLOÏDE. L'INVENTION CONCERNE ENCORE UN CONDITIONNEMENT COMMERCIAL CONTENANT CETTE COMBINAISON.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86744806P | 2006-11-28 | 2006-11-28 | |
US89108807P | 2007-02-22 | 2007-02-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30966B1 true MA30966B1 (fr) | 2009-12-01 |
Family
ID=39386468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31946A MA30966B1 (fr) | 2006-11-28 | 2009-06-03 | Combinaison d'inhibiteurs de iap et d'inhibiteurs de flt3 |
Country Status (20)
Country | Link |
---|---|
US (1) | US8492429B2 (fr) |
EP (1) | EP2089024B1 (fr) |
JP (1) | JP5394249B2 (fr) |
KR (1) | KR20090087094A (fr) |
AT (1) | ATE509629T1 (fr) |
AU (1) | AU2007325280B2 (fr) |
BR (1) | BRPI0719543A2 (fr) |
CA (1) | CA2670498A1 (fr) |
CO (1) | CO6210722A2 (fr) |
EC (1) | ECSP099472A (fr) |
GT (1) | GT200900142A (fr) |
IL (1) | IL198551A0 (fr) |
MA (1) | MA30966B1 (fr) |
MX (1) | MX2009005621A (fr) |
NO (1) | NO20092417L (fr) |
PL (1) | PL2089024T3 (fr) |
PT (1) | PT2089024E (fr) |
RU (1) | RU2456983C2 (fr) |
TN (1) | TN2009000206A1 (fr) |
WO (1) | WO2008067280A2 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2607940C (fr) | 2005-05-18 | 2009-12-15 | Aegera Therapeutics Inc. | Composes liants de domaine bir |
WO2007048224A1 (fr) | 2005-10-25 | 2007-05-03 | Aegera Therapeutics Inc. | Composés de liaison au domaine iap bir |
TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物 |
BRPI0711591A2 (pt) | 2006-05-16 | 2011-11-16 | Aegera Therapeutics Inc | composto de ligação de domìnio bir da iap |
US20100056495A1 (en) * | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
AU2009246347A1 (en) | 2008-05-16 | 2009-11-19 | Dana Farber Cancer Institute, Inc. | Immunomodulation by IAP inhibitors |
US20100317593A1 (en) * | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
SG182724A1 (en) | 2010-02-12 | 2012-08-30 | Pharmascience Inc | Iap bir domain binding compounds |
EP2760446A1 (fr) | 2011-09-30 | 2014-08-06 | Tetralogic Pharmaceuticals Corporation | Mimétique de smac (birinapant) à utiliser dans le traitement de maladies de prolifération (cancer) |
WO2014205516A1 (fr) | 2013-06-25 | 2014-12-31 | The Walter And Eliza Hall Institute Of Medical Research | Methode de traitement d'une infection intracelllulaire |
US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
CN113490497A (zh) | 2019-02-22 | 2021-10-08 | 韩美药品株式会社 | 包括flt3抑制剂和低甲基化剂的用于治疗急性髓系白血病的药物组合物 |
KR20200102948A (ko) | 2019-02-22 | 2020-09-01 | 한미약품 주식회사 | Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물 |
US20220110913A1 (en) | 2019-02-22 | 2022-04-14 | Hanmi Pharm. Co., Ltd | Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia |
AU2020256166A1 (en) | 2019-04-02 | 2021-10-14 | Aligos Therapeutics, Inc. | Compounds targeting PRMT5 |
WO2021220178A1 (fr) | 2020-04-29 | 2021-11-04 | Cominnex Zrt. | Antagonistes d'iap et leurs applications thérapeutiques |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1453661A1 (ru) * | 1972-11-17 | 1989-10-30 | Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе | Противоопухолевое средство "продимин |
BR0312408A (pt) | 2002-07-02 | 2005-04-19 | Novartis Ag | Inibidores de peptìdeo de ligação de proteìna smac a inibidor de apoptose de proteìnas (iap) |
KR20080083220A (ko) * | 2004-04-07 | 2008-09-16 | 노파르티스 아게 | Iap 억제제 |
ES2684120T3 (es) | 2005-12-20 | 2018-10-01 | Novartis Ag | Combinación de un inhibidor de IAP y un taxano |
PE20080951A1 (es) * | 2006-08-02 | 2008-09-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
-
2007
- 2007-11-27 PT PT07868853T patent/PT2089024E/pt unknown
- 2007-11-27 JP JP2009539434A patent/JP5394249B2/ja not_active Expired - Fee Related
- 2007-11-27 AU AU2007325280A patent/AU2007325280B2/en not_active Ceased
- 2007-11-27 US US12/516,062 patent/US8492429B2/en not_active Expired - Fee Related
- 2007-11-27 EP EP07868853A patent/EP2089024B1/fr active Active
- 2007-11-27 KR KR1020097013350A patent/KR20090087094A/ko active IP Right Grant
- 2007-11-27 WO PCT/US2007/085579 patent/WO2008067280A2/fr active Application Filing
- 2007-11-27 AT AT07868853T patent/ATE509629T1/de active
- 2007-11-27 RU RU2009124590/15A patent/RU2456983C2/ru not_active IP Right Cessation
- 2007-11-27 BR BRPI0719543-5A patent/BRPI0719543A2/pt not_active IP Right Cessation
- 2007-11-27 CA CA002670498A patent/CA2670498A1/fr not_active Abandoned
- 2007-11-27 MX MX2009005621A patent/MX2009005621A/es active IP Right Grant
- 2007-11-27 PL PL07868853T patent/PL2089024T3/pl unknown
-
2009
- 2009-05-04 IL IL198551A patent/IL198551A0/en unknown
- 2009-05-22 TN TNP2009000206A patent/TN2009000206A1/fr unknown
- 2009-05-27 GT GT200900142A patent/GT200900142A/es unknown
- 2009-06-03 MA MA31946A patent/MA30966B1/fr unknown
- 2009-06-24 NO NO20092417A patent/NO20092417L/no not_active Application Discontinuation
- 2009-06-25 CO CO09066298A patent/CO6210722A2/es not_active Application Discontinuation
- 2009-06-26 EC EC2009009472A patent/ECSP099472A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20100056467A1 (en) | 2010-03-04 |
AU2007325280A1 (en) | 2008-06-05 |
CO6210722A2 (es) | 2010-10-20 |
EP2089024B1 (fr) | 2011-05-18 |
TN2009000206A1 (en) | 2010-10-18 |
KR20090087094A (ko) | 2009-08-14 |
MX2009005621A (es) | 2009-06-12 |
JP5394249B2 (ja) | 2014-01-22 |
IL198551A0 (en) | 2010-02-17 |
CA2670498A1 (fr) | 2008-06-05 |
PL2089024T3 (pl) | 2011-10-31 |
GT200900142A (es) | 2010-06-24 |
JP2010511059A (ja) | 2010-04-08 |
RU2456983C2 (ru) | 2012-07-27 |
NO20092417L (no) | 2009-08-25 |
WO2008067280A3 (fr) | 2008-08-07 |
ATE509629T1 (de) | 2011-06-15 |
AU2007325280B2 (en) | 2011-03-10 |
PT2089024E (pt) | 2011-08-31 |
ECSP099472A (es) | 2009-10-30 |
EP2089024A2 (fr) | 2009-08-19 |
US8492429B2 (en) | 2013-07-23 |
BRPI0719543A2 (pt) | 2014-02-25 |
WO2008067280A2 (fr) | 2008-06-05 |
RU2009124590A (ru) | 2011-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30966B1 (fr) | Combinaison d'inhibiteurs de iap et d'inhibiteurs de flt3 | |
TW200833662A (en) | 4,5-ring annulated indole derivatives and methods of use thereof | |
GEP20125691B (en) | Compounds and compositions as protein kinase inhibitors | |
MX2009006877A (es) | Derivados indolicos con anillo unido en las posiciones 5,6 y metodos de uso de los mismos. | |
EP2526934A3 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
ECSP066878A (es) | [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa | |
MX2008011633A (es) | Aminoquinolonas como inhibidores de gsk-3. | |
ZA200701629B (en) | Gyrase inhibitors and uses thereof | |
IL192181A0 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder | |
EA200900691A1 (ru) | Применение ингибиторов iap для лечения острого миелоидного лейкоза | |
ATE548034T1 (de) | Pharmazeutische zusammensetzungen mit droxidopa | |
UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
MX2008008556A (es) | Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias. | |
WO2008042480A3 (fr) | Inhibiteurs époxyde de cystéine protéases | |
BRPI0212298B8 (pt) | composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico | |
ATE410154T1 (de) | Pharmazeutische zusammensetzung enthaltend 2,4- dichlorbenzylalkohol und amylmetakresol | |
AR043016A2 (es) | Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene | |
EA200900552A1 (ru) | Пирроло[1,2-а]имидазолдион, эффективный при лечении периферической нейротоксичности, индуцированной химиотерапевтическими агентами | |
MXPA05006408A (es) | Derivados deuterizados de catecolamina y medicamentos comprendiendo estos compuestos. | |
MX2010005009A (es) | Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales. | |
HUP0300576A2 (hu) | Érkárosító hatású, osztott dózisú gyógyászati készítmény | |
WO2006091222A3 (fr) | Methodes de traitement et de prevention du syndrome respiratoire aigu severe (sars) au moyen de avr118 | |
WO2021080188A3 (fr) | Composition pour la prévention ou le traitement de la dépression comprenant un inhibiteur d'expression de protéines et son utilisation | |
AR062215A1 (es) | Inhibidor de trombina activo por via oral | |
AU2016219620A1 (en) | Compositions and methods useful for treatment of respiratory illness |